Author

Yurim Jeong

Observed name: Yurim JEONG

Institution: Inje University

Observed institutions: Inje University, The Catholic University of Korea Yeouido St. Mary's Hospital, Catholic University of Korea

ORCID: 0009-0001-2658-357X

Observed ORCID: 0009-0001-2658-357X

OpenAlex ID: A5056345340

Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway

2025 · Yurim Jeong, Hyewon Jang, et al. · Frontiers in Immunology · 11

Dual Targeting of EZH2 Degradation and EGFR/HER2 Inhibition for Enhanced Efficacy against Burkitt’s Lymphoma

2023 · Se Been Kim, Chae-Eun Yang, et al. · Cancers · 11

Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib

2023 · Yurim Jeong, Se Been Kim, et al. · Frontiers in Oncology · 9

Targeted BTK degradation via PROTACs enhances therapeutic efficacy against lymphoma through synergy with METTL3 inhibitors

2026 · Eunji Na, HwaJeong Kang, et al. · Research Square

Synergistic Effects of Combined PROTAC-based EZH2 Degrader and METTL3 Inhibitor in Burkitt’s Lymphoma

2024 · Minseo YU, Ra Eun KIM, et al. · Korean Journal of Clinical Laboratory Science

Synergistic Inhibition of Burkitt’s Lymphoma with Combined Ibrutinib and Lapatinib Treatment

2023 · Chae-Eun YANG, Se Been KIM, et al. · Korean Journal of Clinical Laboratory Science

Efficacy of Protac-Based EZH2 Degrader MS1943 in Lymphoid Malignancies: A Comprehensive Study on the Combined Effects of MS1943 and Ibrutinib

2023 · Youngwoo Jeon, Yurim Jeong, et al. · Blood

Works count: 7

Citation count: 31

H-index: 3

I10-index: 2